公开(公告)号：US08815288B2

公开(公告)日：2014-08-26

申请号：US13063462

申请日：2010-09-29

Applicant: Huai-Cheng Lee ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Rong Jin Lin

Inventor： Huai-Cheng Lee ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Rong Jin Lin

IPC: A61K9/44

CPC classification number: A61K45/06 ,  A61K9/1635 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/5078 ,  A61K31/13 ,  A61K31/445 ,  A61K2300/00

Abstract: Disclosed herein is an oral dosage formulation that contains both immediate-release and sustained release drugs for treating neurodegenerative disorders. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI) with a dissolution rate of releasing more than 80% of the AChEI within 60 min; and the sustained-release drug is memantine with a dissolution rate of releasing more than 80% of memantine within 12 hours.

Abstract translation: 本文公开了含有用于治疗神经变性疾病的立即释放和缓释药物的口服剂量制剂。 口服剂量制剂中的立即释放药物是乙酰胆碱酯酶抑制剂（AChEI），溶解速率在60分钟内释放超过80％的AChEI; 持续释放药物是在12小时内释放超过80％的美金刚的溶解速率的美金刚。

公开(公告)号：US20130210911A1

公开(公告)日：2013-08-15

申请号：US13509221

申请日：2010-10-25

Applicant: Huai-Cheng Lee ,  Guang-Tzuu Shane ,  Hsi-Chieh Wang ,  Rong Jin Lin

Inventor： Huai-Cheng Lee ,  Guang-Tzuu Shane ,  Hsi-Chieh Wang ,  Rong Jin Lin

IPC: A61K31/277

CPC classification number: A61K31/277

Abstract: Disclosed herein are methods and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L receptor. The method comprises administering a composition comprising an effective amount of verapamil and a pharmaceutically acceptable excipient to a subject, wherein the verapamil is capable of binding to at least one of a receptor selected from the group consisting of orexin receptor 1, orexin receptor 2, somatostatin receptor 2 and dopamine D2L receptor of the subject.

Abstract translation: 本文公开了用于治疗与食欲肽受体1，食欲肽受体2，生长抑素受体2或多巴胺D2L受体相关的疾病或病症的方法和组合物。 该方法包括向受试者施用包含有效量的维拉帕米和药学上可接受的赋形剂的组合物，其中所述维拉帕米能够结合至少一种选自食欲肽受体1，食欲素受体2，生长抑素 受体2和受体的多巴胺D2L受体。

公开(公告)号：US20120177735A1

公开(公告)日：2012-07-12

申请号：US13063462

申请日：2010-09-29

Applicant: Huai-Cheng Lee ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Rong Jin Lin

Inventor： Huai-Cheng Lee ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Rong Jin Lin

IPC: A61K31/445 ,  A61P25/28 ,  A61P25/00 ,  A61K9/00 ,  A61K9/44

CPC classification number: A61K45/06 ,  A61K9/1635 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/5078 ,  A61K31/13 ,  A61K31/445 ,  A61K2300/00

Abstract: Disclosed herein is an oral dosage formulation that contains both immediate-release and sustained release drugs for treating neurodegenerative disorders. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI) with a dissolution rate of releasing more than 80% of the AChEI within 60 min; and the sustained-release drug is memantine with a dissolution rate of releasing more than 80% of memantine within 12 hours.

Abstract translation: 本文公开了含有用于治疗神经变性疾病的立即释放和缓释药物的口服剂量制剂。 口服剂量制剂中的立即释放药物是乙酰胆碱酯酶抑制剂（AChEI），溶解速率在60分钟内释放超过80％的AChEI; 持续释放药物是在12小时内释放超过80％的美金刚的溶解速率的美金刚。